AGREEMENT
BY AND BETWEEN:
On behalf of UNIVERSITE PARIS V, XXXX XXXXXXXXX, Department of Pharmaceutical
and Biological Sciences (FACULTE DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES),
00 Xxx xx x'Xxxxx xx Xxxxxxxx, 00000, Xxxxx XXXXX 00, Xxxxxx, represented by its
President, Xx. Xxxxxx Xxxxxxx, duly authorized for the purposes hereof,
Hereinafter referred to as the "University"
AND:
DRUGABUSE SCIENCES SAS, a French simplified corporation (SOCIETE PAR ACTIONS
SIMPLIFIEE), having its principal office at 0 Xxx xx Xxxxx, 00000, Xxxxxx,
Xxxxxx, and represented by Xxx. Xxxxxxxxx Xxxxxx in her capacity as Chief
Executive Officer, duly authorized for the purposes hereof,
Hereinafter referred to as "DAS SAS"
AND:
DRUGABUSE SCIENCES INC., a corporation organized under the laws of California,
having its principal office at Menlo Park, California, USA, and represented by
Dr. Philippe Pouletty in his capacity as Chairman of the Board of Directors,
duly authorized for the purposes hereof,
Hereinafter referred to as "DAS Inc."
RECITALS
WHEREAS, The DAS Group develops anti-cocaine antibodies, known as [****], for
the treatment of addicts.
DAS SAS develops these antibodies at its premises located within the Department
of Pharmaceutical and Biological Sciences of Universite de Paris V, Xxxx
Xxxxxxxxx, with which DAS SAS has signed an agreement covering occupation of the
premises and delivery of services. DAS has also recently signed, on
June 8, 1999, production and licensing agreements with Pasteur Merieux Serums &
Vaccins, a subsidiary of Rhone Poulenc.
DAS is developing the COC-AB product worldwide through the various companies
within the DAS Group.
Patent applications have been filed for the antibodies in Europe and the United
States in DAS Inc.'s name.
DAS SAS is a subsidiary of DAS Inc.
NOW, THEREFORE, IT HAS BEEN AGREED AS FOLLOWS:
ARTICLE 1
In this agreement, the following terms will have the meanings ascribed to them
below:
1.1 "Antibody" means the [****].
1.2 "DAS Group" means DAS SAS and DAS Inc., including their respective
subsidiaries, meaning those companies in which they hold at least 50% of
the capital stock and/or voting rights and whose business concerns the
marketing of the Antibody.
1.3 "Net Sales" means the amount effectively received by the DAS Group
worldwide from the sale of the Antibody to independent third parties
(including but not limited to sub-licensees and distributors) less:
[****]
[****]
[****]
[****]
ARTICLE 2
The DAS Group undertakes to commercialize the Antibody worldwide, through DAS
SAS within France and DAS Inc. and its subsidiaries for the rest of the world.
ARTICLE 3
3.1 In consideration for the knowledge and know-how contributed by the
University and the work performed under the arrangement for delivery of
services specified above, the DAS Group undertakes to [****] by the DAS
Group.
3.2 The total cumulative amount [****]
3.3 [****], which constitute the University's [****], will be paid [****]
3.4 DAS SAS undertakes to [****] it will [****]
ARTICLE 4
4.1 The DAS Group will retain exclusive legal title in and to all patentable
and non-patentable inventions related to the COC-AB antibodies developed
by Universite de Paris V, Xxxx Xxxxxxxxx, provided the goal of the
research and development work in question is the Antibody or improved
versions thereof.
2
These patentable and non-patentable inventions will not give rise to any
compensation in addition to that defined in Article 3 above. Universite de Paris
V, Xxxx Xxxxxxxxx, hereby waives all present and future industrial property
rights concerning COC-AB products and technologies, including in particular the
products covered by the DAS Group's patents and patent applications
No. US 5817 770 and No. PCT/US98/05450.
4.2 Universite de Paris V will promptly notify the various research and
development service providers referred to in subsection 4.1 above of
their obligation to inform DAS SAS of any patentable or non-patentable
results achieved and to assist the staff responsible for such inventions
to obtain patent protection, where applicable. In all cases, the staff
responsible for the invention will be listed as being the inventors in
any resulting applications for industrial property protection.
ARTICLE 5
The contracting parties undertake to keep all information covered by this
agreement strictly confidential. In addition, they undertake to ensure that all
research and development information will only be disclosed to their employees
or various service providers on a strictly need-to-know basis.
Information held by a party will be deemed to be non-confidential if it is:
- Already in the public domain before disclosure to another party; or
- Disclosed to the public other than by an act or omission of another
party; or
- Disclosed to the other party by a third party not bound by any
confidentiality obligation.
ARTICLE 6
The present Agreement is governed by French law.
Any disputes arising under this agreement or in relation thereto will be
referred to the competent Paris Courts.
3
Signed in Paris on June 8, 1999,
In three original copies, comprising one for each party.
For Universite de Paris V:
Xx. Xxxxxx Xxxxxxx
President
/s/ Xxxxxx Xxxxxxx
----------------------
Xxxxxx Xxxxxxx
For DAS SAS: For DAS Inc.:
/s/ Xxxxxxxxx Xxxxxx /s/ Philippe Pouletty
----------------------- ----------------------------------------
Xxxxxxxxx Xxxxxx Dr. Philippe Pouletty
Chief Executive Officer Chairman of the Board of Director
4
